Overview

Update
Total Equity Funding
$295.44M in 5 Rounds from 8 Investors
Most Recent Funding
$106M Series E on March 25, 2015
Headquarters:
South San Francisco, CA
Description:
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Founders:
Categories:
Biopharma, Biotechnology, Medical
Website:
http://www.ngmbio.com

Company Details

Update

NGM Biopharmaceuticals, Inc. is a privately held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the Company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. Our current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.

Funding Rounds (5) - $295.44M

Update
DateAmount / RoundValuationLead InvestorInvestors
Mar, 2015$106M / Series E1
Mar, 2015$57.5M / Series D4
Jul, 2013$50M / Series C5
Nov, 2011$55.39M / Series B4
Dec, 2009$26.55M / Series A3

Current Team (9)

Update

Board Members and Advisors (4)

Update

Offices/Locations (1)

Update
  • Office

    630 Gateway Blvd

    South San Francisco, CA 94080-7014

    USA

Past Team (1)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos